Top 8 Developed Pancreatic Adenocarcinoma Therapeutics Markets Examined in In-demand GBI Research Study Published at MarketPublishers.com
13 May 2014 • by Natalie Aster
LONDON – In 2012, the worldwide pancreatic adenocarcinoma therapeutics market stood at around USD 856 million. Furthermore, in 2019, it is predicted to reach USD 1.2 billion. The growth will likely be spurred by small changes in manifold factors, including the influence of the drugs expected to be approved through to 2019, rising prevalence of the disease, and slight improvements in diagnostics.
Masivet/Kinavet, Tertomotide, Glufosfamide, TH-302, MM-398 and HyperAcute Pancreas make up the promising drug candidates in the pancreatic adenocarcinoma therapeutics pipeline. AB Science, Kael-GemVax, Eleison Pharmaceuticals Incorporated, Threshold Pharmaceuticals, Merrimack Pharmaceuticals and NewLink Genetics Corporation are amid the dominant players in the global pancreatic adenocarcinoma therapeutics market.
In-demand report “Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant” prepared by GBI Research contains an extensive analysis on the 8 leading developed markets for pancreatic adenocarcinoma therapeutics – the UK, France, the UK, Germany, Canada, Italy, Japan and Spain.
An up-close look at the markets’ historical evolution and current scenario supplemented with a complete set of market performance indicators is provided in the in-demand report. The study includes a comprehensive profile of the disease, offers a detailed analysis of available pancreatic adenocarcinoma drugs, encompassing details on their efficacy, safety, treatment patterns and weaknesses/strengths; and also provides an all-round overview of the pancreatic adenocarcinoma therapies pipeline. It also offers an in-depth examination of pipeline drug clinical trials, touches upon the co-development and licensing deals landscape in the field, sheds light on the market growth barriers and drivers. Besides, the study grants access to multi-scenario forecast data on the major developed pancreatic adenocarcinoma markets along with a summary of the expected market trends.
Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant
Published: April, 2014
Price: US$ 3,500.00
Other Recent Studies by GBI Research:
- HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth
- Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers
- NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool
More in-demand reports by the publisher can be found at GBI Research page.